• Nexalin flagged two clinical abstracts accepted for the 2026 NYC Neuromodulation Conference; results will be presented at the meeting.
• Data came from an open-label pilot trial in adults with generalized anxiety disorder and comorbid insomnia using its non-invasive brain-stimulation device.
• Outcomes showed broad symptom improvement across anxiety, depressive symptoms, insomnia, and quality of life, with benefits described as durable post-treatment.
• Safety profile appeared favorable, with no serious adverse events reported in the study.
• Disclosure supports its push toward international commercialization, including a potential Brazil launch, alongside an FDA De Novo pathway strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160915PRIMZONEFULLFEED9747123) on June 16, 2026, and is solely responsible for the information contained therein.